Advanced or Metastatic Solid Tumors

Oncology
14
Pipeline Programs
11
Companies
13
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
10
4
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 13 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Erasca
ErascaSAN DIEGO, CA
3 programs
2
1
ERAS-007Phase 1/21 trial
ERAS-601Phase 11 trial
NaporafenibPhase 1Small Molecule1 trial
Active Trials
NCT04670679Active Not RecruitingEst. Feb 2026
NCT05907304Active Not RecruitingEst. Dec 2026
NCT04866134Active Not RecruitingEst. Nov 2025
E
EisaiChina - Liaoning
1 program
1
E7050Phase 1/21 trial
Active Trials
NCT01355302Terminated7Est. Jul 2013
Takeda
TakedaTOKYO, Japan
1 program
1
TAK-188Phase 1/21 trial
Active Trials
NCT07205718Recruiting223Est. Dec 2029
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
1
W0101 - Cohort A1Phase 1/21 trial
Active Trials
NCT03316638Terminated316Est. Jul 2022
DynamiCure
DynamiCureMA - Waltham
2 programs
2
DCBY02Phase 11 trial
DCSZ11Phase 11 trial
Active Trials
NCT05496595TerminatedEst. Feb 2024
NCT05785754RecruitingEst. Dec 2026
Coherus Oncology
Coherus OncologyCA - Redwood City
1 program
1
CHS-1000Phase 11 trial
Active Trials
NCT06389526Not Yet Recruiting48Est. May 2028
One Biosciences
One BiosciencesFrance - Paris
1 program
1
DAY301Phase 11 trial
Active Trials
NCT06752681RecruitingEst. Dec 2028
IDEAYA Biosciences
IDEAYA BiosciencesSOUTH SAN FRANCISCO, CA
1 program
1
IDE-161Phase 1
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
RXDX-106Phase 11 trial
Active Trials
NCT03454243Terminated1Est. Jun 2018
Taiho Oncology
Taiho OncologyNJ - Princeton
1 program
1
TAS0612Phase 11 trial
Active Trials
NCT04586270TerminatedEst. Nov 2024
TG Therapeutics
TG TherapeuticsNEW YORK, NY
1 program
1
TGI-6 InjectionPhase 11 trial
Active Trials
NCT06374173RecruitingEst. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
TakedaTAK-188
ErascaERAS-007
Pierre FabreW0101 - Cohort A1
EisaiE7050
Coherus OncologyCHS-1000
One BiosciencesDAY301
TG TherapeuticsTGI-6 Injection
ErascaNaporafenib
DynamiCureDCSZ11
DynamiCureDCBY02
ErascaERAS-601
Taiho OncologyTAS0612
RocheRXDX-106

Clinical Trials (13)

Total enrollment: 595 patients across 13 trials

NCT07205718TakedaTAK-188

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

Start: Nov 2025Est. completion: Dec 2029223 patients
Phase 1/2Recruiting
NCT04866134ErascaERAS-007

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Start: May 2021Est. completion: Nov 2025
Phase 1/2Active Not Recruiting
NCT03316638Pierre FabreW0101 - Cohort A1

A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors

Start: Nov 2017Est. completion: Jul 2022316 patients
Phase 1/2Terminated
NCT01355302EisaiE7050

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Start: Nov 2011Est. completion: Jul 20137 patients
Phase 1/2Terminated
NCT06389526Coherus OncologyCHS-1000

A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

Start: Feb 2025Est. completion: May 202848 patients
Phase 1Not Yet Recruiting
NCT06752681One BiosciencesDAY301

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

Start: Nov 2024Est. completion: Dec 2028
Phase 1Recruiting
NCT06374173TG TherapeuticsTGI-6 Injection

A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors

Start: Jan 2024Est. completion: Dec 2027
Phase 1Recruiting
NCT05907304ErascaNaporafenib

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Start: Aug 2023Est. completion: Dec 2026
Phase 1Active Not Recruiting
NCT05785754DynamiCureDCSZ11

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Start: Jun 2023Est. completion: Dec 2026
Phase 1Recruiting
NCT05496595DynamiCureDCBY02

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Start: Oct 2022Est. completion: Feb 2024
Phase 1Terminated
NCT04670679ErascaERAS-601

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Start: Dec 2020Est. completion: Feb 2026
Phase 1Active Not Recruiting
NCT04586270Taiho OncologyTAS0612

A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

Start: Oct 2020Est. completion: Nov 2024
Phase 1Terminated
NCT03454243RocheRXDX-106

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Start: Feb 2018Est. completion: Jun 20181 patients
Phase 1Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 595 patients
11 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)